Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker
- PMID: 34110373
- DOI: 10.1001/jamaoncol.2021.1867
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker
Comment in
-
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-Reply.JAMA Oncol. 2021 Aug 1;7(8):1245-1246. doi: 10.1001/jamaoncol.2021.1870. JAMA Oncol. 2021. PMID: 34110358 No abstract available.
Comment on
-
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.JAMA Oncol. 2021 May 1;7(5):739-743. doi: 10.1001/jamaoncol.2020.7684. JAMA Oncol. 2021. PMID: 33599686 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
